Compare Amphastar Pharmaceuticals Inc (AMPH) vs Wells Fargo & Co (WFC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Wells Fargo (WFC) trades at $87.12, up 0.24% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows steady revenue growth to $83.70B in 2025 and net income of $21.34B, with a P/E of 13.47 suggesting reasonable valuation. Recent news highlights anticipation for Q2 2026 earnings on July 14, 2026, with analysts expecting EPS of $1.73. The dividend of $0.45 per share was paid in June 2026, supporting income investors.

Outlook is cautiously optimistic with a consensus price target of $99.44, implying 14% upside, though risks include volatile cash flows and regulatory scrutiny. Earnings misses in recent quarters warrant monitoring, but improving net interest income and fee growth could drive positive surprises. Investor sentiment is balanced with 45% buy ratings, but macroeconomic pressures on banks remain a headwind.